Metabolic Syndrome-Related Kidney Injury: A Review and Update

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Jul 11

PMID 35813613

Authors

Lirong Lin

Wei Tan

Xianfeng Pan

En Tian

Zhifeng Wu

Jurong Yang

Affiliations

Soon will be listed here.

Abstract

Metabolic syndrome (MetS) includes visceral obesity, hyperglycemia, dyslipidemia, and hypertension. The prevalence of MetS is 20-25%, which is an important risk factor for chronic kidney disease (CKD). MetS causes effects on renal pathophysiology, including glomerular hyperfiltration, RAAS, microalbuminuria, profibrotic factors and podocyte injury. This review compares several criteria of MetS and analyzes their differences. MetS and the pathogenesis of CKD includes insulin resistance, obesity, dyslipidemia, inflammation, oxidative stress, and endothelial dysfunction. The intervention of MetS-related renal damage is the focus of this article and includes controlling body weight, hypertension, hyperglycemia, and hyperlipidemia, requiring all components to meet the criteria. In addition, interventions such as endoplasmic reticulum stress, oxidative stress, gut microbiota, body metabolism, appetite inhibition, podocyte apoptosis, and mesenchymal stem cells are reviewed.

Citing Articles

Associations between kidney function with all-cause and cause-specific mortality in type 2 diabetes mellitus patients: a prospective cohort study in China.

He J, Wan Y, Fan X, Yu H, Qin Y, Su J J Health Popul Nutr. 2025; 44(1):77.

PMID: 40083037 PMC: 11907967. DOI: 10.1186/s41043-025-00809-2.

Nonlinear relationship between serum Klotho and chronic kidney disease in US adults with metabolic syndrome.

Lin X, Yang L Front Endocrinol (Lausanne). 2025; 15():1409560.

PMID: 39777219 PMC: 11703749. DOI: 10.3389/fendo.2024.1409560.

Metabolic Syndrome, Kidney-Related Adiposity, and Kidney Microcirculation: Unraveling the Damage.

Jang K, Hur J, Lee D, Kim S Biomedicines. 2025; 12(12.

PMID: 39767613 PMC: 11673429. DOI: 10.3390/biomedicines12122706.

Magnolol Inhibits High Fructose-Induced Podocyte Inflammation via Downregulation of TKFC/Sp1/HDAC4/Notch1 Activation.

Zhou Z, Wang Y, Xing Y, Pan S, Wang W, Yang J Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598328 PMC: 11597211. DOI: 10.3390/ph17111416.

Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD: A UK Biobank Study.

Bilson J, Hydes T, McDonnell D, Buchanan R, Scorletti E, Mantovani A Liver Int. 2024; 45(4):e16159.

PMID: 39548715 PMC: 11897864. DOI: 10.1111/liv.16159.

References

Monhart V . [Treatment of dyslipidemia in patients with metabolic syndrome and chronic kidney disease]. Vnitr Lek. 2009; 55(7-8):671-8. View

Nagasawa K, Matsuura N, Takeshita Y, Ito S, Sano Y, Yamada Y . Attenuation of cold stress-induced exacerbation of cardiac and adipose tissue pathology and metabolic disorders in a rat model of metabolic syndrome by the glucocorticoid receptor antagonist RU486. Nutr Diabetes. 2016; 6:e207. PMC: 4855259. DOI: 10.1038/nutd.2016.14. View

Owusu J, Barrett E . Early Microvascular Dysfunction: Is the Vasa Vasorum a "Missing Link" in Insulin Resistance and Atherosclerosis. Int J Mol Sci. 2021; 22(14). PMC: 8303323. DOI: 10.3390/ijms22147574. View

Chang A, Chen Y, Still C, Wood G, Kirchner H, Lewis M . Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int. 2016; 90(1):164-71. PMC: 4912457. DOI: 10.1016/j.kint.2016.02.039. View

Li J, Li J, Ni J, Zhang C, Jia J, Wu G . Berberine Relieves Metabolic Syndrome in Mice by Inhibiting Liver Inflammation Caused by a High-Fat Diet and Potential Association With Gut Microbiota. Front Microbiol. 2022; 12:752512. PMC: 8790126. DOI: 10.3389/fmicb.2021.752512. View

Wu N, Qin Y, Chen S, Yu C, Xu Y, Zhao J . Association between metabolic syndrome and incident chronic kidney disease among Chinese: A nation-wide cohort study and updated meta-analysis. Diabetes Metab Res Rev. 2021; 37(7):e3437. DOI: 10.1002/dmrr.3437. View

Saklayen M . The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018; 20(2):12. PMC: 5866840. DOI: 10.1007/s11906-018-0812-z. View

Vatier C, Jeru I, Fellahi S, Capeau J, Bastard J, Vigouroux C . [Leptin, adiponectin, lipodystrophic and severe insulin resistance syndromes]. Ann Biol Clin (Paris). 2020; 78(3):261-264. DOI: 10.1684/abc.2020.1551. View

Kang S, Cho K, Park J, Yoon K, Do J . Association of visceral fat area with chronic kidney disease and metabolic syndrome risk in the general population: analysis using multi-frequency bioimpedance. Kidney Blood Press Res. 2015; 40(3):223-30. DOI: 10.1159/000368498. View

10.

Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Doumas M, Athyros V . Hypertension in Metabolic Syndrome: Novel Insights. Curr Hypertens Rev. 2019; 16(1):12-18. DOI: 10.2174/1573402115666190415161813. View

11.

Rodriguez-Rodriguez A, Donate-Correa J, Luis-Lima S, Diaz-Martin L, Rodriguez-Gonzalez C, Perez-Perez J . Obesity and metabolic syndrome induce hyperfiltration, glomerulomegaly, and albuminuria in obese ovariectomized female mice and obese male mice. Menopause. 2021; 28(11):1296-1306. DOI: 10.1097/GME.0000000000001842. View

12.

Hirode G, Wong R . Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016. JAMA. 2020; 323(24):2526-2528. PMC: 7312413. DOI: 10.1001/jama.2020.4501. View

13.

Hosseini A, Razavi B, Banach M, Hosseinzadeh H . Quercetin and metabolic syndrome: A review. Phytother Res. 2021; 35(10):5352-5364. DOI: 10.1002/ptr.7144. View

14.

Aminian A, Daigle C, Romero-Talamas H, Kashyap S, Kirwan J, Brethauer S . Risk prediction of complications of metabolic syndrome before and 6 years after gastric bypass. Surg Obes Relat Dis. 2014; 10(4):576-82. DOI: 10.1016/j.soard.2014.01.025. View

15.

Lopes H, Correa-Giannella M, Consolim-Colombo F, Egan B . Visceral adiposity syndrome. Diabetol Metab Syndr. 2016; 8:40. PMC: 4950710. DOI: 10.1186/s13098-016-0156-2. View

16.

Gu P, Xu A . Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction. Rev Endocr Metab Disord. 2013; 14(1):49-58. DOI: 10.1007/s11154-012-9230-8. View

17.

Esmaili S, Hemmati M, Karamian M . Physiological role of adiponectin in different tissues: a review. Arch Physiol Biochem. 2018; 126(1):67-73. DOI: 10.1080/13813455.2018.1493606. View

18.

Rizzo M, Nikolic D, Patti A, Mannina C, Montalto G, McAdams B . GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(9 Pt B):2814-2821. DOI: 10.1016/j.bbadis.2018.05.012. View

19.

Goncalves L, Miot H, Domingues M, Oliveira C . Autopsy Patients With Obesity or Metabolic Syndrome as Basic Cause of Death: Are There Pathological Differences Between These Groups?. Clin Med Insights Pathol. 2018; 11:1179555718791575. PMC: 6066805. DOI: 10.1177/1179555718791575. View

20.

Stuard S, Belcaro G, Cesarone M, Ricci A, Dugall M, Cornelli U . Kidney function in metabolic syndrome may be improved with Pycnogenol®. Panminerva Med. 2010; 52(2 Suppl 1):27-32. View